{'fraction_non_alphanumeric': 0.02574416733708769, 'fraction_numerical': 0.017699115044247787, 'mean_word_length': 5.038834951456311, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Preparation and characterization of human colon tumor-associated antigen and its clinical significance].

AIM
To purify the colon tumor-associated antigen from cultured colon tumor cells, and to investigate its expression in the sera of patients with colon cancer.


METHODS
The monoclonal antibody (mAb) against human colon tumor-associated antigen 4D10 was employed as the ligand for the immunoaffinity chromatography to purify the colon tumor-associated antigen from the lysate of colorectal tumor cell LOVO. The purified antigen was identified by SDS-PAGE and Western blot. The expression of colon tumor-associated antigen in the sera of patients with colon cancer and in normal sera was detected by Sandwich ELISA.


RESULTS
The purified colon tumor-associated antigen binding to mAb 4D10 was a heterodimer composed of two subunits with relative molecular mass M(r) of 30 x 10(3) and 35 x 10(3) respectively. The antigen was significantly higher expressed in sera from patients with colon cancer than that in normal sera (P<0.01).


CONCLUSION
The tumor-associated antigen obtained from the colon tumor cells has been successfully purified through immunoaffinity chromatography with mAb 4D10, which may be useful for diagnosis on clinic.